Codiak Announces Pricing of $57.8 Million Public Offering of Common Stock

科迪亚克公司宣布公开发行5780万美元普通股的定价

2021-02-12 18:00:14 BioSpace

本文共1200个字,阅读需3分钟

CAMBRIDGE, Mass., Feb. 11, 2021 -- Codiak BioSciences, Inc. , a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, announced today the pricing of its underwritten public offering of 2,750,000 shares of its common stock at a public offering price of $21.00 per share, for gross proceeds of approximately $57.8 million, before deducting underwriting discounts and commissions and offering expenses. All of the shares are being offered by Codiak. In addition, Codiak has granted the underwriters a 30-day option to purchase up to an additional 412,500 shares of its common stock, at the public offering price, less underwriting discounts and commissions. All the shares to be sold in the proposed offering will be sold by Codiak. The offering is expected to close on February 17, 2021, subject to customary closing conditions. Goldman Sachs & Co. LLC, Evercore ISI and William Blair are acting as joint book-running managers for the offering and as representatives of the underwriters. Wedbush PacGrow is acting as lead manager for the offering. A registration statement relating to these securities has been filed with the Securities and Exchange Commission (“SEC”) and became effective on February 11, 2021. This offering is being made only by means of a prospectus. Copies of the final prospectus may be obtained, when available, on the SEC’s website at http://www.sec.gov or by contacting Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, or by email: prospectus-ny@ny.email.gs.com; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, telephone: (888) 474-0200, or by email: ecm.prospectus@evercore.com; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, telephone: 1-800-621-0687, or by email: prospectus@williamblair.com. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About Codiak Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.
马萨诸塞州,剑桥,2021年2月11日--Codiak BioSciences,Inc.是一家临床阶段的生物制药公司,专注于开拓以外泌体为基础的疗法作为一种新的药物的开发,今天宣布了其承销公开发行2750,000股普通股的定价,公开发行价格为每股21.00美元,在扣除承销折扣、佣金和发行费用之前,总收入约为5780万美元。所有股份均由Codiak提供。此外,Codiak已授予承销商30天的选择权,以公开发行价格,减去承销折扣和佣金,购买最多412,500股普通股。建议发售中出售的所有股份将由Codiak出售。 发售预计于2021年2月17日截止,但须遵守惯常截止条件。 高盛、Evercore ISI和William Blair将担任此次发行的联合账簿管理人和承销商代表。Wedbush PacGrow将担任此次发行的主要经理人。 与这些证券相关的注册声明已向美国证券交易委员会(“SEC”)备案,并于2021年2月11日生效。本次发售仅以招股章程方式进行。最终招股说明书的副本可以在SEC的网站上获得,网址是http://www.sec.gov,也可以联系高盛公司,联系电话:ProcessTus Department,200 West Street,New York,New York 10282,电话:1-866-471-2526,或者通过电子邮件:processTus-ny@ny.email.gs.com;或Evercore Group L.L.C.,注意:Equity Capital Markets,55 East 52 Street,36 Floor,New York,NY 10055,电话:(888)474-0200,或通过电子邮件:ecm.prospectus@Evercore.com;或William Blair&Company,L.L.C.,地址:伊利诺伊州芝加哥北河滨广场150号招股说明书部,电话:1-800-621-0687,或通过电子邮件:Prospectus@williamblair.com。 本新闻稿不构成出售或购买这些证券的要约,也不应在任何州或司法管辖区内提供或出售这些证券,在该州或司法管辖区根据任何此类州或司法管辖区的证券法注册或资格之前,该要约、邀约或出售将是非法的。 关于科迪亚克 科迪亚克是一家临床阶段的生物制药公司,专注于开拓基于外泌体的疗法的发展,这是一种新型药物,有潜力改变一系列疾病的治疗,有很高的医疗需求未得到满足。通过利用外泌体的生物学特性作为细胞间的自然转移机制,Codiak开发了其专有的engEx平台,以扩展外泌体的固有特性,设计、设计和制造新型的外泌体治疗候选物。Codiak利用其engEx平台生成了一条深度的工程外泌体管道,旨在治疗广泛的疾病领域,包括肿瘤学、神经肿瘤学、神经病学、神经肌肉疾病和感染性疾病。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文